Acumen Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

William F Goure

Paul J Shughrue

Weirong Wang

Fubao Wang

Wei-Qin Zhao

Alexander McCampbell

Renee C Gaspar

Ningyan Zhang

Todd R Pray

Grant A Krafft

Min Xu

Mary J Savage

Abigail L Wolfe

Franz F Hefti

Nigyan Zhang

Todd Pray

Alexander Mccampbell

This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.

Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

This invention is a selective A&#x3b2; oligomer kit and immunoassay method capable of reliably and sensitively detecting A&#x3b2; oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A&#x3b2; oligomer antibodies, as capture and detection antibodies, to detect and quantify A&#x3b2; oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.

Antibodies, kit and method for detecting amyloid beta oligomers

Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid &#x3b2;oligomers from amyloid &#x3b2;monomers. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid &#x3b2;oligomers.

Methods of modifying amyloid &#x3b2; oligomers using non-peptidic compounds

Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from A&#x3b2;monomers.

Methods of restoring cognitive ability using non-peptidic compounds

Growing community of inventors

Livermore, CA, United States of America

William F Goure